{"id":3666,"date":"2025-04-12T12:10:41","date_gmt":"2025-04-12T09:10:41","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3666"},"modified":"2025-04-12T12:23:14","modified_gmt":"2025-04-12T09:23:14","slug":"satellos-sat-3247-stem-cell-approach-may-restore-muscle-regeneration-in-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/satellos-sat-3247-stem-cell-approach-may-restore-muscle-regeneration-in-duchenne-muscular-dystrophy\/","title":{"rendered":"Satellos SAT-3247 K\u00f6k H\u00fccre Yakla\u015f\u0131m\u0131 Duchenne Musk\u00fcler Distrofi&#039;de Kas Yenilenmesini Geri Kazand\u0131rabilir"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Ekzon atlama veya gen terapisi gibi genetik m\u00fcdahaleler, distrofin kayb\u0131n\u0131 telafi etmeyi ama\u00e7lar, ancak yeni kas h\u00fccreleri olu\u015fturmak i\u00e7in gereken eksik sinyali yerine koymaz. Satellos SAT-3247 K\u00f6k H\u00fccre Terapisi ise distrofinden tamamen ba\u011f\u0131ms\u0131z olarak v\u00fccudun do\u011fal rejeneratif mekanizmalar\u0131n\u0131 kullan\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kas b\u00fct\u00fcnl\u00fc\u011f\u00fcn\u00fc korumak i\u00e7in gerekli bir protein olan distrofinin Duchenne kas distrofisinde (DMD) bulunmad\u0131\u011f\u0131 uzun zamand\u0131r bilinmektedir. Tedavi giri\u015fimlerinin \u00e7o\u011fu, distrofini geri kazand\u0131rmak i\u00e7in gen terapisi, ekzon atlama veya di\u011fer genetik teknikleri kullanmak \u00fczerine olmu\u015ftur. Ancak, son \u00e7al\u0131\u015fmalar, distrofinin yap\u0131sal destek sa\u011flaman\u0131n yan\u0131 s\u0131ra kas rejenerasyonunu kontrol etmek i\u00e7in de gerekli oldu\u011funu g\u00f6stermektedir. Bu ke\u015fifle yepyeni bir terap\u00f6tik yakla\u015f\u0131m m\u00fcmk\u00fcn hale gelmi\u015ftir.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#satellos-sat-3247-approach\">Satellos SAT-3247 Yakla\u015f\u0131m\u0131<\/a><\/li><li><a href=\"#differences-of-sat-3247-from-dystrophin-focused-therapies\">SAT-3247&#039;nin Distrofin Odakl\u0131 Terapilerden Farklar\u0131<\/a><\/li><li><a href=\"#challenges-in-the-sat-3247-process\">SAT-3247 Faz 1 Klinik Denemesi<\/a><\/li><li><a href=\"#verification-of-sat-3247-activity\">SAT-3247 Aktivitesinin Do\u011frulanmas\u0131<\/a><\/li><li><a href=\"#which-patients-can-receive-sat-3247\">Hangi Hastalara SAT-3247 Uygulanabilir?<\/a><\/li><li><a href=\"#sat-3247-price-and-equitable-access\">SAT-3247 Fiyat ve E\u015fit Eri\u015fim<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"satellos-sat-3247-approach\">Satellos SAT-3247 Yakla\u015f\u0131m\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Michael Rudnicki&#039;nin ara\u015ft\u0131rmas\u0131na g\u00f6re distrofin, kas h\u00fccrelerinin b\u00fct\u00fcnl\u00fc\u011f\u00fcn\u00fc koruman\u0131n yan\u0131 s\u0131ra kas k\u00f6k h\u00fccrelerinin asimetrik olarak b\u00f6l\u00fcnmesine neden olan bir sinyal proteini olarak g\u00f6rev yapar. Her asimetrik h\u00fccre b\u00f6l\u00fcnmesi hem yeni bir k\u00f6k h\u00fccre hem de bir kas progenit\u00f6r h\u00fccresi \u00fcretti\u011finden, bu mekanizma kas rejenerasyonu ve onar\u0131m\u0131 i\u00e7in \u00e7ok \u00f6nemlidir. (<a href=\"https:\/\/satellos.com\/press\/drug-target-review-sat-3247-a-new-small-molecule-approach-to-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Daha fazla bilgi edin<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Distrofin sinyalinin yoklu\u011funda yetersiz asimetrik b\u00f6l\u00fcnmeler meydana gelir ve bu da progenitor h\u00fccrelerin eksikli\u011fine ve kademeli, g\u00fc\u00e7s\u00fczle\u015ftirici kas atrofisine neden olur. DMD&#039;yi ba\u015far\u0131s\u0131z kas rejenerasyonu hastal\u0131\u011f\u0131 olarak yeniden tan\u0131mlayarak, bu bulgular Satellos&#039;nin i\u015flevi iyile\u015ftirmeye ve v\u00fccudun do\u011fal rejenerasyon yoluyla yeni kas \u00fcretme yetene\u011fini yeniden kazanmaya odaklanmas\u0131na yard\u0131mc\u0131 oldu.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"differences-of-sat-3247-from-dystrophin-focused-therapies\">SAT-3247&#039;nin Distrofin Odakl\u0131 Terapilerden Farklar\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Satellos, rejenerasyonu geri kazand\u0131rmayan distrofini genetik olarak geri kazand\u0131rmaya \u00e7al\u0131\u015fmak yerine asimetrik h\u00fccre b\u00f6l\u00fcnmelerini geri kazand\u0131rarak kas rejenerasyonunu te\u015fvik etmenin bir yolunu arad\u0131. Sonu\u00e7 olarak, adapt\u00f6r ili\u015fkili protein kinaz 1&#039;i bloke eden t\u00fcr\u00fcn\u00fcn ilk \u00f6rne\u011fi k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7 olan SAT-3247 yarat\u0131ld\u0131. SAT-3247, bu proteini inhibe ederek h\u00fccrelerin asimetrik olarak b\u00f6l\u00fcnmesi ve progenitor kas h\u00fccreleri \u00fcretmesi i\u00e7in gereken sinyali geri kazand\u0131r\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Satellos, bunun hayvan modellerinde ve in vitro&#039;da iyi \u00e7al\u0131\u015ft\u0131\u011f\u0131n\u0131 g\u00f6stermi\u015ftir. Satellos y\u00f6ntemi, distrofin kayb\u0131n\u0131 telafi etmek i\u00e7in gen terapisi veya ekzon atlama gibi genetik teknikler kullanan mevcut tedavilerden \u00f6nemli \u00f6l\u00e7\u00fcde farkl\u0131d\u0131r. Satellos y\u00f6ntemi, distrofinden tamamen ba\u011f\u0131ms\u0131z olan v\u00fccudun do\u011fal rejeneratif s\u00fcre\u00e7lerini kullan\u0131rken, di\u011fer y\u00f6ntemler yeni kas h\u00fccreleri olu\u015fturma s\u00fcrecinde kaybolan sinyali geri y\u00fcklemez.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"challenges-in-the-sat-3247-process\">SAT-3247 Faz 1 Klinik Denemesi<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Satellos taraf\u0131ndan Eyl\u00fcl 2024&#039;te SAT-3247&#039;nin farmakokineti\u011fini ve g\u00fcvenli\u011fini de\u011ferlendirmek i\u00e7in Faz 1 randomize, plasebo kontroll\u00fc bir ara\u015ft\u0131rma ba\u015flat\u0131ld\u0131. \u015eu anda tamamlanm\u0131\u015f olan bu ilk fazda 72 sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fc tedavi edildi ve birka\u00e7 tek ve artan doz (SAD\/MAD) kohortunun yan\u0131 s\u0131ra bir \u00e7apraz g\u0131da etkisi kohortunu kaps\u0131yordu. SAT-3247&#039;nin g\u00fcvenli\u011fini ve hastalar\u0131n PK profillerini de\u011ferlendirmek i\u00e7in \u015fu anda devam eden ikinci a\u015famada on yeti\u015fkin DMD hastas\u0131 Satellos ile tedavi edilecek. Bu ara\u015ft\u0131rmalar\u0131n yard\u0131m\u0131yla farmakodinamik g\u00f6stergeler de bulunabilir. (<a href=\"https:\/\/dmdwarrior.com\/tr\/satellos-announces-completed-enrollment-of-phase-1-clinical-trial-of-sat-3247-in-healthy-volunteers\/\">SAT-3247&#039;nin 1. Faz Klinik \u00c7al\u0131\u015fmas\u0131<\/a>)<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"verification-of-sat-3247-activity\">SAT-3247 Aktivitesinin Do\u011frulanmas\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SAT-3247&#039;nin Faz 1 geli\u015fimi son derece olumlu bir g\u00fcvenlik profili g\u00f6stermi\u015ftir. A\u011f\u0131zdan al\u0131nabilen k\u00fc\u00e7\u00fck bir molek\u00fcl ilac\u0131 oldu\u011fundan, di\u011fer terapilerde g\u00f6r\u00fclmeyen esneklik ve tolerans sunabilir. Distrofin restorasyonundan ziyade rejenerasyona odakland\u0131\u011f\u0131 i\u00e7in birincil veya tamamlay\u0131c\u0131 bir terapi olarak kullan\u0131labilir, bu da \u00f6nceki tedaviden ba\u011f\u0131ms\u0131z olarak daha geni\u015f bir DMD hasta grubuna yard\u0131mc\u0131 olabilir. Dahas\u0131, bu tedavi hastal\u0131\u011f\u0131n seyrini yava\u015flatmaktan ziyade kas onar\u0131m\u0131n\u0131 iyile\u015ftirerek erken ve daha belirgin klinik faydalar sa\u011flayabilir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"which-patients-can-receive-sat-3247\">Hangi Hastalara SAT-3247 Uygulanabilir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bu tedavi, mutasyona \u00f6zg\u00fc onar\u0131m yerine kas rejenerasyonuna odakland\u0131\u011f\u0131 i\u00e7in genetik yap\u0131lar\u0131 ne olursa olsun t\u00fcm DMD hastalar\u0131na yard\u0131mc\u0131 olma potansiyeline sahiptir. Ayr\u0131ca, klinik \u00f6ncesi ara\u015ft\u0131rmalar, mevcut tedavilerle kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, SAT-3247&#039;nin rejeneratif \u00f6zelliklerinin kas fonksiyonunu daha erken art\u0131rabilece\u011fini g\u00f6stermektedir. Bu hayvan ara\u015ft\u0131rmalar\u0131ndan hangi hasta alt gruplar\u0131n\u0131n en fazla fayda sa\u011flad\u0131\u011f\u0131n\u0131 ve gelecekteki klinik \u00e7al\u0131\u015fmalarla bunlar\u0131n insan hastalara uygulan\u0131p uygulanmayaca\u011f\u0131n\u0131 belirlemek m\u00fcmk\u00fcn olacakt\u0131r.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"sat-3247-price-and-equitable-access\">SAT-3247 Fiyat ve E\u015fit Eri\u015fim<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">K\u00fc\u00e7\u00fck bir molek\u00fcl ilac\u0131 olan SAT-3247, gen tedavilerine g\u00f6re \u00fcretim ve da\u011f\u0131t\u0131m kolayl\u0131\u011f\u0131 gibi \u00e7e\u015fitli avantajlara sahiptir. Bu y\u00f6ntem, mutasyona \u00f6zg\u00fc olmad\u0131\u011f\u0131 i\u00e7in t\u00fcm DMD hastalar\u0131na da sunulabilir ve bu da eri\u015filebilirli\u011fi kolayla\u015ft\u0131r\u0131r. Bu tedavi piyasaya \u00e7\u0131kt\u0131\u011f\u0131nda, Satellos yayg\u0131n ve adil eri\u015fim sa\u011flamak i\u00e7in yetkililer ve t\u0131p uzmanlar\u0131yla i\u015f birli\u011fi yapmaya adanm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Devam\u0131n\u0131 oku:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/tr\/satellos-presents-initial-data-from-the-phase-1-trial-of-sat-3247-at-the-2025-muscular-dystrophy-association-clinical-scientific-conference\/\">Satellos, SAT-3247&#039;nin 1. Faz Denemesinden \u0130lk Verileri Sunuyor<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Genetic interventions such as exon skipping or gene therapy aim to compensate for the loss of dystrophin, but do not replace the missing signal needed to create new muscle cells. Satellos SAT-3247 Stem Cell Therapy, on the other hand, uses the body\u2019s natural regenerative mechanisms completely independent of dystrophin. It has long been known that [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3669,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[282],"tags":[254,251,252,253],"class_list":["post-3666","post","type-post","status-publish","format-standard","has-post-thumbnail","category-editorials","tag-frank-gleeson","tag-sat-3247","tag-satellos","tag-satellos-bioscience"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=3666"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3666\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/3669"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=3666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=3666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=3666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}